Madrid, 18 dic (EFE). – The Consorcio Centro de Investigación Biomédica en Red (CIBER) in the Barcelona Supercomputing Center-Centro Nacional de Supercomputación (BSC-CNS) Technology (IMPaCT).
The convocatoria associated with this initiative amounts to 25.8 million euros in direct aid, which the CIBER and the BSC-CNS, informed the four Ministries of Science and Innovation in a communication.
Marked in the Strategic Action in Health 2017-2020 of the Institute of Health Carlos III (ISCIII), the convocatoria is one step closer to the implementation of the Precision Medicine in the National Health System that, underwent a strategy based on the science and innovation, compared to 2020 and 2021 with 77.3 million euros for its development.
The programs included in IMPaCT are aligned with three areas that will be developed in the future national strategy: Predictive Medicine, Genomic Medicine and Date Science.
The CIBER is charged with the management of the first two, to be compared with a financing of 14 million and 7.24 million, respectively, while the BSC-CNS will cover the third, with a financing of 4.55 million.
In each of the three professional participating programs of more than one centenary of Spanish institutions and sanitary institutions, led by a person who acts as coordinator and responsible of the action plan.
The Predictive Medicine program is coordinated by Marina Pollán from the CIBER of Epidemiology and Public Health (CIBERESP); El de Medicina Genómica, by Ángel Carracedo from the CIBER de Raras (CIBERER), and the Ciencia de Datos, by Alfonso Valencia from the BSC-CNS.
The Predictive Medicine program runs with the participation of 21 more institutions between hospitals and research centers of all Spain; Medical Medicine will have a network of five genomic analysis centers and a group of clinical experts, and the Scientific Data Center participates in 47 institutions along with companies, foundations, universities and research centers.
The Predictive Medicine program is launching a population cohort of residents in Spain that will generate a dynamic register of clinical, epidemiological and habitat data of the population that will help to take decisions in health, construct predictive models and predictive models evaluate the impact of sanitary policies.
“The IMPaCT cohort will include, in its final draw, 200,000 people representing the entire Spanish population. For its large size and wide geographical coverage, it will allow to represent the ethnic variability and the geographical and ambient diversity of all Pisa elisa.
The Genome Medicine Program develops infrastructures and coordination protocols to implement genomic analysis and other ‘local’ data throughout the national territory, as well as supportive technologies for the ultimate generation and experience of human diagnosis.
The objective is to provide experimental diagnostic ‘technology’ to service all those who have a diagnostic effort with maximum assistive technology, which does not have a basic diagnostic step to increase seniority the persons and the National Health System.
“This initiative has an important key to the SNS and that genomic medicine represents a revolution in sanitary assistance. Allows diagnostics, identifies the best treatments and designs prevention strategies,” said Angel Carracedo.
Finally, the Data Science program will continue to support the development of a common, interoperable and integrated system, collecting and analyzing clinical and molecular data related to the knowledge and resources available under the Spanish Science and Technology System. of research from the various clinical and molecular information systems available.
Basically, this program ensures that investigators can have a public perspective based on individual data.
“With the science data program we want to initiate the construction of infrastructure and systems to be able to integrate genomic and medical data now has dispersed, providing technical solutions to the numbers of heterogeneity, dispersion and access problems; and center the bases on the development of precision medicine research projects “, concluded Alfonso Valencia. EFE